Cardiac Science taps Kardikar as new CEO
Cardiac Science said last week it named Devdatt Kurdikar as its new CEO.
Kurdikar previously served as Boston Scientific’s men’s health biz general manager, the company said.
“The board is excited to announce Dev’s appointment as CEO to lead Cardiac Science through the next phase of its growth. Dev is a highly accomplished healthcare executive with an outstanding track record of success, and his experience leading global operations for major medical device businesses will be a tremendous asset to Cardiac Science. We look forward to a long, productive partnership with Dev and the exceptionally strong leadership team at Cardiac Science,” board chair Sean Ozbolt said in a press release.
“I am honored to be appointed CEO of this world-class organization, and I am excited about the opportunity to help lead the continued resurgence of Cardiac Science. For over 25 years, this company has played a critical role in saving victims of sudden cardiac arrest around the world, and we will continue to support this mission as we expand our product lines and global presence. Today, Cardiac Science is growing meaningfully and there is an extraordinary passion to win at every level of the organization, and I look forward to working with this impressive team to build on the company’s success,” Kurdikar said in prepared remarks.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.